Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and a leading cause of dementia. Its pathology is multifactorial and includes the accumulation of amyloid-beta (Aβ), abnormal tau phosphorylation, oxidative stress, neuroinflammation, synaptic dysfunction and impairment of cholinergic neurotransmission. Available medicines can provide symptomatic benefit, but the complexity of AD continues to motivate the search for complementary therapeutic candidates. Glycyrrhiza glabra L., commonly known as licorice or mulethi, is a medicinal plant used in traditional systems of medicine. Its roots contain several classes of phytoconstituents, including triterpenoid saponins, flavonoids, isoflavones, chalcones and phenolic compounds. Constituents such as glycyrrhizin, glycyrrhetinic acid, liquiritin, isoliquiritin and glabridin have been associated in the literature with anti-inflammatory, antioxidant and other pharmacological activities. These properties provide a rationale for investigating whether G. glabra may influence biological processes relevant to AD. However, evidence for general antioxidant or anti-inflammatory activity should not be interpreted as proof of clinical efficacy in AD. This review synthesizes the supplied literature on AD pathology, the phytochemical profile and pharmacological activities of G. glabra, and identifies research gaps concerning target-specific mechanisms, extract standardization, bioavailability, safety and translational validation. Phytochemical characterization combined with in vitro assays, computational screening and carefully designed in vivo studies may help determine whether specific constituents have meaningful neuroprotective potential. [19,21,25,3,15,22]
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: